Named as a key player in 33 of our reports, across 33 regions and countries.
[1] ClinicalTrials.gov, Studies led by Broad Institute of MIT and Harvard or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
Our reports that name Broad Institute of MIT and Harvard as a key player, by category and place.
Markets where they are a key player. Each opens the market's statistics for every place we cover.
None of their markets match.
Our newest markets with them as a key player. Each covers 2024 history, a 2025 base year and forecasts to 2034.
Named as key players in the same markets as Broad Institute of MIT and Harvard (number of shared markets).
Bio-Rad Laboratories1 shared market
Data4Cure1 shared market
Illumina, Inc.1 shared market
Perkin Elmer1 shared market
Qiagen N.V.1 shared market
Quest Diagnostics1 shared market
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
1 active study led by Broad Institute of MIT and Harvard, of 1 in all
Source: ClinicalTrials.gov, Studies with Broad Institute of MIT and Harvard (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
The topics of the markets Broad Institute of MIT and Harvard is in.
Stories on the topics Broad Institute of MIT and Harvard works in.
Behind every insurance claim is a standard electronic message. The CAQH Index says $20 billion a year could…
Read
Sequencing a human genome fell from about $50 million in 2003 to under $1,500 by late 2015. Bioinformatics…
Read
Medicare estimated $31.7 billion in improper fee-for-service payments in 2024. Better billing, cleaner…
ReadSearch all reports for Broad Institute of MIT and Harvard All companies